Buser K, Delaloye J F
Département de gynécologie-obstétrique, CHUV, Lausanne.
Rev Med Suisse Romande. 2000 Jun;120(6):511-3.
Chemoprevention of breast cancer, a dream? In one American study (National Surgical Adjuvant Breast and Bowel Project, NSABP-P1) tamoxifen decreased the incidence of invasive and non-invasive breast cancer, whereas in two English and Italian studies, it did not reduce this risk. Differences in the study population for the trials may underly these conflicting findings. New drugs, the SERMs, may be more promising.
乳腺癌的化学预防,只是一个梦?在美国的一项研究(国家外科辅助乳腺和肠道项目,NSABP-P1)中,他莫昔芬降低了浸润性和非浸润性乳腺癌的发病率,而在两项英国和意大利的研究中,它并未降低这种风险。这些试验中研究人群的差异可能是这些相互矛盾的结果的潜在原因。新型药物,即选择性雌激素受体调节剂(SERM),可能更具前景。